Back to Journals » Journal of Experimental Pharmacology » Volume 13

Experimental Serotonergic Agents for the Treatment of Schizophrenia

Authors Capuzzi E, Caldiroli A, Ciscato V, Russo S, Buoli M

Received 23 November 2020

Accepted for publication 16 January 2021

Published 5 February 2021 Volume 2021:13 Pages 49—67

DOI https://doi.org/10.2147/JEP.S259317

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Professor Bal Lokeshwar


Enrico Capuzzi,1 Alice Caldiroli,1 Veronica Ciscato,2 Stefania Russo,2 Massimiliano Buoli3,4

1Psychiatric Department, Azienda Socio Sanitaria Territoriale Monza, Monza, Italy; 2Department of Medicine and Surgery, University of Milano Bicocca, Monza, MB, 20900, Italy; 3Department of Neurosciences and Mental Health, Fondazione IRCCS Ca’Granda Ospedale Maggiore Policlinico, Milan, 20122, Italy; 4Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

Correspondence: Massimiliano Buoli
Department of Neurosciences and Mental Health, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Via F. Sforza 35, Milan, 20122, Italy
Tel +39-02-55035983
Fax +39-02-55035952
Email massimiliano.buoli@unimi.it

Abstract: Schizophrenia remains one of the most chronic and highly disabling mental disorder. To date, the pathomechanism of schizophrenia is not fully understood and current treatments are characterized by some limitations. First- and second-generation antipsychotics have shown clinical efficacy in treating positive symptoms, while are poorly effective on both negative symptoms and cognitive deficits. Moreover, they can involve many metabolic and neurological side effects, leading to low therapeutic compliance. Many evidence suggested that serotonin may play a complex role in the neurobiology of schizophrenia. Therefore, new drugs targeting 5-HT receptors (5-HTRs) have become an important area of research in schizophrenia in the hope that treatment efficacy may be improved without inducing side effects observed with currently available antipsychotics. Research using the main database sources was conducted to obtain an overview of preclinical and clinical pharmacological 5-HTR-targeted therapies in patients with schizophrenia. We identified 17 experimental serotonergic agents, under study for their potential use in schizophrenia treatment. Particularly, AVN-211, LuAF-35700 and Brilaroxazine are currently under clinical development. Moreover, some compounds showed some pro-cognitive and antipsychotic-like properties in animal models, while other agents showed contradictory effects in improving symptoms and were removed from the development program. Although some serotonergic drugs seem promising for improving the treatment of schizophrenia, further studies regarding the pathophysiological mechanisms of schizophrenia and novel compounds as well as high-quality trials are necessary in order to improve schizophrenia outcomes.

Keywords: schizophrenia, serotonin, experimental agents, negative symptoms, cognitive deficits

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]